Ultimovacs – executive interview Test

Ultimovacs – executive interview Test

Ultimovacs — 7 videos in collection

Ultimovacs is a Scandinavian-based biotech focused on developing novel immunotherapies in combination with checkpoint inhibitors against cancer. Its lead product candidate, UV1, is a universal off-the-shelf peptide-based vaccine being studied in ongoing Phase II clinical trials across five indications. The innovative oncology vaccine targets the cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has broad potential in a variety of settings and would increase accessibility.

In this interview, Ultimovacs CMO Jens Bjørheim recaps the company’s progress and provides a preview of the upcoming rich newsflow.


You may also be interested in these:

Healthcare

Ultimovacs – executive interview

Ultimovacs

Healthcare

Ultimovacs - executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.